This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Four placebo-controlled trials and four other unspecified studies evaluating short term pain relief and reduction of complications or prevention of transmission; one published review of clinical trials assessing the efficacy of acyclovir in shingles.
Methods of combining primary studies
The results of each trial were pooled. The exact method was not stated.
Investigation of differences between primary studies
Differences were not investigated. The best and worst results were reported for shingles. No explanation for the differences was given.
Results of the review
Acyclovir shortens the symptoms of chickenpox by an average of one day in adults and children. About 20% of children had symptoms shortened by up to three days. There was no evidence that acyclovir had any effect on reduction of complications or prevention of transmission of chickenpox. In patients with shingles, acyclovir reduced the mean duration of pain by 10 days. It reduced the incidence of postherpetic neuralgia by 8% (2% and 32% in the worst and best single trial results).
Measure of benefits used in the economic analysis
Shortening of symptoms measured in days.
Direct costs
Costs and quantities were analysed separately. Information on the formulation used and the dosage of acyclovir was collected. This was provided by the Medicines Monitoring Unit in Dundee. The cost of acyclovir was based on information given by the British National Formulary, 1992. The costs of consultation with a GP was given, which included administration and time costs. This cost information was obtained from the literature (1991). The cost boundary adopted was the health service.
